Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odevixibat - Albireo AB

Drug Profile

Odevixibat - Albireo AB

Alternative Names: A-4250

Latest Information Update: 13 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Albireo AB
  • Developer Albireo AB; Albireo Pharma
  • Class Acetamides; Antipruritics; Butyric acids; Hepatoprotectants; Small molecules; Sulfones; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis; Biliary atresia; Intrahepatic cholestasis; Alagille syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Intrahepatic cholestasis
  • Phase II Primary biliary cirrhosis; Pruritus
  • Phase I Alagille syndrome
  • No development reported Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Aug 2019 Albireo Pharma anticipates first regulatory approval and launch of odevixibat for Intrahepatic cholestasis in 2021
  • 05 Aug 2019 Chemical structure information added
  • 09 Jul 2019 Albireo Pharma plans a pivotal trial for Biliary atresia (PO), in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top